Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Aethlon Medical Inc AEMD

Healthcare Medical Devices
Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based... see more

Opinion & Analysis (NDAQ:AEMD)

    Exosome Sciences uncovers biomarker candidate to ID Players with CTE

    The Life Sciences Report May 6, 2016

    Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary

    Gail Dutton December 23, 2015

    Aethlon Medical's biofiltration platform tackles everything from ebola to cancer: CEO James Joyce

    Gail Dutton October 30, 2015

    Eight ways to leverage the small-cap biotech bull market: Ajay Tandon and Jay Albany of SeeThruEquity

    Gail Dutton October 30, 2015

    Cutting-edge devices and diagnostics deliver drugs and profits: Cantor Fitzgerald's Caroline Corner

    George S. Mack July 31, 2015

    Four small-cap medtech primed for outsize returns: Zacks' Brian Marckx

    The Life Sciences Report July 15, 2015